Home Antibody All anti-IRAK4 antibodies
Anti-IRAK4 Antibody Y279
Also for IRAK4 (NM_016123)
|A synthetic peptide corresponding to residues in the N-term of human IRAK-4 was used as immunogen.|
||0.5~1.0 mg/ml (Lot Dependent)
||ICC: 1:50 - 1:100; IHC-P: Use a concentration of 1 ug/ml; WB: 1:1000 - 1:10000
|Does not react with Mouse, Rat. Is unsuitable for Flow Cyt or IP.|
|PBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
|Is unsuitable for Flow Cyt or IP.
|Homo sapiens interleukin-1 receptor-associated kinase 4 (IRAK4), transcript variant 2|
|IPD1; IRAK-4; NY-REN-64; REN64|
|This gene encodes a kinase that activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. The protein is essential for most innate immune responses. Mutations in this gene result in IRAK4 deficiency and recurrent invasive pneumococcal disease. Multiple transcript variants encoding different isoforms have been found for this gene. [supplied by RefSeq]. |
Toll-like receptor signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot - IRAK4 antibody [Y279]; Anti-IRAK4 antibody [Y279] at 1/500 dilution + Jurkat cell lysate.Observed band size : 52 kDa .
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IRAK4 antibody [Y279]; IHC image ofab32511 staining in human spleenformalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with TA303793, 1ug/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.